US Patent

US8962572 — Bortezomib formulations

Formulation · Assigned to Fresenius Kabi USA LLC · Expires 2032-11-03 · 6y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a bortezomib composition that includes bortezomib and boric acid in a specific mass ratio, which can be prepared as a solid through lyophilization.

USPTO Abstract

A bortezomib composition includes bortezomib and boric acid in a mass ratio of boric acid to bortezomib is from 1:1 to 10:1. The composition is a solid, and may be prepared by forming a liquid mixture including a solvent, bortezomib and boric acid, and lyophilizing the liquid mixture.

Drugs covered by this patent

Patent Metadata

Patent number
US8962572
Jurisdiction
US
Classification
Formulation
Expires
2032-11-03
Drug substance claim
No
Drug product claim
Yes
Assignee
Fresenius Kabi USA LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.